Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study

Overview of attention for article published in Multiple Sclerosis and Related Disorders, September 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

blogs: 1 blog
policy: 2 policy sources

wikipedia: 3 Wikipedia pages

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab. A health technology assessment.

Cited by Norwegian Institute of Public Health on 27 Aug 2019

The Norwegian Institute of Public Health is a government agency under the Ministry of Health and Care Services. Our employees are located in Oslo, Bergen, Levanger, Tynset og Trondheim.

cladribine - Clinical Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 24 Oct 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.